Drug updated on 5/17/2024
Dosage Form | Aerosol (inhalation; fluticasone propionate/salmeterol; 45 mcg/21 mcg, fluticasone propionate/salmeterol; 115 mcg/21 mcg, fluticasone propionate/salmeterol; 230 mcg/21 mcg) |
Drug Class | Corticosteroids and long-acting beta2-adrenergic agonists |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for treatment of asthma in adult and adolescent patients aged 12 years and older.
Latest News
![loading GIF](/img/news-loading.gif)
Summary
- Fluticasone propionate and salmeterol (Advair HFA) is indicated for the treatment of asthma in adults and adolescents aged 12 years and older. It has been shown to significantly improve health-related quality of life compared to placebo, long-acting beta-agonists alone, or inhaled corticosteroids only.
- Five systematic reviews/meta-analyses focused on the effectiveness and safety of Advair HFA in comparison with other medications for treating asthma.
- The safety profile of fluticasone propionate/salmeterol was comparable to that of the formoterol/budesonide combination therapies among adults and adolescents. Nonetheless, there is a lack of studies focusing on the children population subgroup.
- In terms of efficacy against pediatric asthma management, fluticasone propionate/salmeterol demonstrated clearer improvements than fluticasone propionate/formoterol, particularly regarding primary lung function measures and related symptom scores.
- For chronic obstructive pulmonary disease (COPD), LABA/LAMA combinations generally showed more effectiveness than ICS/LABA options like Advair HFA at improving trough FEV1 levels while reducing exacerbation risk. However, this does not diminish the importance or relevance of Advair HFA, especially when dealing with overlap between COPD and asthma conditions.
- The overall conclusion from these studies suggests that despite some treatments offering advantages over others depending on specific contexts such as purely COPD cases vs. asthma-COPD overlaps, etc., it remains crucial to consider individual needs effectively by tailoring treatment plans accordingly based on multifaceted comparisons across different drug profiles.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Advair HFA (fluticasone propionate and salmeterol) Prescribing Information. | 2023 | GlaxoSmithKline, Durham, NC |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: a network meta-analysis. | 2022 | Respiratory Medicine |
Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. | 2021 | The Cochrane Database of Systematic Reviews |
Comparing the efficacy and safety of formoterol/budesonide pMDI versus its mono-components and other LABA/ICS in patients with asthma. | 2020 | Respiratory Medicine |
The efficacy and safety of fluticasone propionate/formoterol compared with fluticasone propionate/salmeterol in treating pediatric asthma: a systematic review and meta-analysis. | 2020 | Journal of International Medical Research |
Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: a network meta-analysis. | 2019 | Pulmonary Pharmacology and Therapeutics |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
How do we manage asthma? Assessment of knowledge, attitude, and practice patterns among pulmonologists and allergists. | 2023 | The Journal of Asthma |
2022 GINA report, global strategy for asthma management and prevention. | 2022 | Global Initiative for Asthma |
Asthma guideline updates. | 2022 | ACSAP: Pulmonary Care |
Are the Global Initiative for Asthma (GINA) Guidelines Being Correctly Used to Diagnose Severe Asthma in the UAE? | 2020 | Cureus |